echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Immune combined targeting program for liver cancer translational therapy expert consensus is released to help breakthroughs in liver cancer treatment

    Immune combined targeting program for liver cancer translational therapy expert consensus is released to help breakthroughs in liver cancer treatment

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The Fifth Yangtze River Delta Liver Disease Summit Forum and Seminar on Multidisciplinary Diagnosis and Treatment of Liver Tumors in 2021 was held in Hefei recently.


    Infection diagnosis and treatment

    Hepatocellular carcinoma (HCC) is a hot topic discussed at this conference.


    "Liver cancer is a malignant disease with a high incidence, high fatality rate, and high recurrence rate.


    "Liver cancer is a malignant disease with a high incidence, high fatality rate, and high recurrence rate.


    On May 27, 2021, the " Consensus of Chinese Experts on Transformation Therapy of Advanced Hepatocellular Carcinoma Based on Immune Combination Targeting Program (2021 Edition)" (hereinafter referred to as "Consensus") press conference was held in Beijing .


    Immune checkpoint inhibitors represented by PD-1/PDL-1 inhibitors, combined with targeted therapy and local treatment, are expected to successfully transform some patients with advanced liver cancer, and improve the prognosis of patients through comprehensive treatment centered on surgery


    Professor Lu Shichun of the Department of Hepatobiliary and Pancreatic Surgery of the Chinese People’s Liberation Army General Hospital mentioned that hepatocellular carcinoma accounts for 75%-90% of the total number of primary liver cancers, and up to 39.


    Dr.


    Professor Li Gong of Beijing Tsinghua Chang Gung University Hospital mentioned that the treatment plan of ICIs combined with AATDs is simple and convenient for patients, even at home, and related adverse reactions can be relieved by themselves or only need to be treated symptomatically.


    Professor Bi Xinyu from the Cancer Hospital of the Chinese Academy of Medical Sciences mentioned that surgical treatment of advanced hepatocellular carcinoma after transformation is safe and feasible, but the surgical method is relatively complicated.


    Experts also said that immune checkpoint inhibitors (ICIs) combined with anti-angiogenesis targeted drugs (AATDs) to treat advanced hepatocellular carcinoma will also be the breakthrough and main direction for improving the overall 5-year survival rate of the liver cancer population in the next ten years.


    This conference was jointly sponsored by the Hepatology Group of the Surgery Branch of the Beijing Medical Association, the Chinese Journal of Hepatobiliary Surgery Committee, and the Hepatobiliary and Pancreatic Disease Prevention and Control Professional Committee of the Chinese Preventive Medicine Association


    Professor He Xiaodong from Peking Union Medical College Hospital stated at the meeting that the combination of ICIs and AATDs, or superimposing other applicable local treatments, to form a further three-dimensional transformational treatment plan opened up a new direction for the treatment of advanced hepatocellular carcinoma.


    Next, the "Chinese Expert Consensus on Translational Therapy of Advanced Hepatocellular Carcinoma Based on Immune Combined Targeting Program (2021 Edition)" will be promoted nationwide.


    Professor Weidong Xiao

    Chief Physician of the First Affiliated Hospital of University of Science and Technology of China

    Professor, PhD supervisor, PhD

      Department of Liver Surgery, First Affiliated Hospital of Chinese University of Science and Technology

      Member of International Liver Cancer Association/Member of International Hepatobiliary and Pancreatic Association

      Member of the Hepatology Group of the Chinese Medical Association Surgery Branch

      Member of the Liver Cancer Group of the Oncology Branch of the Chinese Medical Association

      Member of the Liver Cancer Group of the Chinese Society of Liver Diseases

      Member of the Standing Committee of the Liver Cancer Professional Committee of the Chinese Anti-Cancer Association

      Member of the Standing Committee of the Liver Cancer Professional Committee of the Chinese Medical Doctor Association and Chairman of the Intelligent Diagnosis and Treatment Committee

      Standing Committee Member of the Liver Cancer Expert Committee of the Chinese Society of Clinical Oncology

      Member of the Standing Committee of the Liver Surgeons Committee of the Chinese Medical Doctor Association Surgeons Branch

      Member of the National Cancer Center Liver Cancer Quality Control Expert Committee

      Deputy Chairman of the Surgery Branch of Anhui Medical Association and Leader of the Hepatobiliary and Pancreatic Surgery Group

      Chairman of the Liver Cancer Professional Committee of Anhui Anti-Cancer Association



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.